Blueprint Medicines Corp
BPMC
Market Cap$7.3B
Close$
$95.39
17% downside
Current Fair Value
17% downsideOvervalued by 17% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.30 Billion |
|---|---|
| Enterprise Value | $7.66 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-8.37 |
| Beta | 0.59 |
| Outstanding Shares | 63,381,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -56.88 |
|---|---|
| PEG | 98.21 |
| Price to Sales | 19.15 |
| Price to Book Ratio | 28.73 |
| Enterprise Value to Revenue | 17.64 |
| Enterprise Value to EBIT | -29 |
| Enterprise Value to Net Income | -60 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Blueprint Medicines Corp
CEO: Jeffrey Albers